Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Ocular Therapeutix: $23.8m in new funding will help advance eye therapies

Ocular Therapeutix Inc., a Bedford company looking to use is proprietary hydrogel technology to commercialize treatments for eye ailments, said Monday that it recently closed a Series D extension round of financing totaling $23.8 million.

All existing institutional investors, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures participated in the round, Ocular Therapeutix said in a press release.

Continue reading below

The company said it has raised about $65 million to date.

Ocular Therapeutix plans to use the funding to advance drug candidates in its pipeline.

They include travoprost, which is designed to treat glaucoma, and dexamethasone, which looks to relieve post-operative inflammation and pain.

The funds will also be used to develop sustained release therapies for retinal diseases in collaboration with pharma partners, Ocular Therapeutix said.

Another product the company is working on is called ReSure Sealant, which would be used to seal clear corneal incisions following lens implantation surgery.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com